The role of CDK4/6 inhibitors in early breast cancer.

The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in...

Descripción completa

Detalles Bibliográficos
Autores: Gil-Gil, M, Alba, E, Gavila, J, de la Haba-Rodriguez, J, Ciruelos, E, Tolosa, P, Candini, D, Llombart-Cussac, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p10836
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/10836
Access Level:acceso abierto
Palabra clave:Abemaciclib
Adjuvant therapy
Cyclin-dependent kinase 4/6 inhibitors
Early breast cancer
Palbociclib
id ES_f368405c8f37a40d7ffd57aecee7058e
oai_identifier_str oai:fisabio.fundanetsuite.com:p10836
network_acronym_str ES
network_name_str España
repository_id_str
spelling The role of CDK4/6 inhibitors in early breast cancer.Gil-Gil, MAlba, EGavila, Jde la Haba-Rodriguez, JCiruelos, ETolosa, PCandini, DLlombart-Cussac, AAbemaciclibAdjuvant therapyCyclin-dependent kinase 4/6 inhibitorsEarly breast cancerPalbociclibThe use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.CHURCHILL LIVINGSTONE2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/10836BREASTISSN: 09609776ISSNe: 15323080reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p108362026-06-11T12:45:17Z
dc.title.none.fl_str_mv The role of CDK4/6 inhibitors in early breast cancer.
title The role of CDK4/6 inhibitors in early breast cancer.
spellingShingle The role of CDK4/6 inhibitors in early breast cancer.
Gil-Gil, M
Abemaciclib
Adjuvant therapy
Cyclin-dependent kinase 4/6 inhibitors
Early breast cancer
Palbociclib
title_short The role of CDK4/6 inhibitors in early breast cancer.
title_full The role of CDK4/6 inhibitors in early breast cancer.
title_fullStr The role of CDK4/6 inhibitors in early breast cancer.
title_full_unstemmed The role of CDK4/6 inhibitors in early breast cancer.
title_sort The role of CDK4/6 inhibitors in early breast cancer.
dc.creator.none.fl_str_mv Gil-Gil, M
Alba, E
Gavila, J
de la Haba-Rodriguez, J
Ciruelos, E
Tolosa, P
Candini, D
Llombart-Cussac, A
author Gil-Gil, M
author_facet Gil-Gil, M
Alba, E
Gavila, J
de la Haba-Rodriguez, J
Ciruelos, E
Tolosa, P
Candini, D
Llombart-Cussac, A
author_role author
author2 Alba, E
Gavila, J
de la Haba-Rodriguez, J
Ciruelos, E
Tolosa, P
Candini, D
Llombart-Cussac, A
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Abemaciclib
Adjuvant therapy
Cyclin-dependent kinase 4/6 inhibitors
Early breast cancer
Palbociclib
topic Abemaciclib
Adjuvant therapy
Cyclin-dependent kinase 4/6 inhibitors
Early breast cancer
Palbociclib
description The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR(+)) and human epidermal growth factor receptor 2-negative (HER2(-)) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/10836
url https://fisabio.portalinvestigacion.com/publicaciones/10836
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv CHURCHILL LIVINGSTONE
publisher.none.fl_str_mv CHURCHILL LIVINGSTONE
dc.source.none.fl_str_mv BREAST
ISSN: 09609776
ISSNe: 15323080
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424374652600320
score 15,81155

Similares en LA Referencia